Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07083479 | Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma(AMPLIFY-EAP) | no longer available | — | — | Elicio TherapeuticsINDUSTRY | 0 | Jul 10, 2026 | clinicaltrials |
| NCT07399015 | Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC | no longer available | — | — | Endevica BioINDUSTRY | 0 | Feb 18, 2026 |
| clinicaltrials |
| NCT03756311 | Expanded Access to NanoPac | no longer available | — | — | NanOlogy, LLCINDUSTRY | 0 | Jan 23, 2026 | clinicaltrials |
| NCT04087889 | Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer | no longer available | — | — | Hope Biosciences LLCINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02449135 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Carcinoma | no longer available | — | — | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT04137822 | Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer | no longer available | — | — | Impatients N.V. trading as myTomorrowsINDUSTRY | 2 | Aug 14, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2026source: clinicaltrials